Study Investigators Defend Stivarga’s Benefit
Reporting the results of the CORRECT trial in colorectal cancer in the Lancet Nov. 22, study investigators built a case that regorafenib should be a new standard of care, despite criticism of the effect size, toxicity and cost.
You may also be interested in...
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.
Patients with the most severe type of disease were all randomized to treatment with the study drug, which may have had a negative impact on outcome, the Israeli company suggested.